<tt id="6hsgl"><pre id="6hsgl"><pre id="6hsgl"></pre></pre></tt>
          <nav id="6hsgl"><th id="6hsgl"></th></nav>
          国产免费网站看v片元遮挡,一亚洲一区二区中文字幕,波多野结衣一区二区免费视频,天天色综网,久久综合给合久久狠狠狠,男人的天堂av一二三区,午夜福利看片在线观看,亚洲中文字幕在线无码一区二区
               
           
          Home> News
          China and Cuba co-develop new anti-cancer vaccine
          (chinadaily.com.cn)
          Updated: 2012-03-29
           

          Jointly developed by China and Cuba, a new kind of vaccine used to treat non-small-cell lung cancer (NSCLC) has obtained the approval of China's State Food and Drug Administration. It is about to conduct clinical tests at the Chinese Academy of Medical Sciences (CAMS).

          The news was released at the China-Cuba Biopharmaceutical Achievement Analysis and Prospect Conference, held by the Biotech Pharmaceuticals Co Ltd.

          Dr. Agustín Lage Dávila is the director of the Center of Molecular Immunology and is a renowned biotechnologist in Cuba. He said, "After diagnosis, the development of the tumor will usually disappear and recur with therapy progress."

          Dr. Lage said Cimavax, the new vaccine that was jointly developed by Cuba and Biotech, is a conjugated vaccine that recombines the epidermal growth factor (EGF). As a therapeutic vaccine, it directs the EGF required by tumor expansion and prevents the further proliferation of tumor tissues. It thereby keeps the tumor at a stable level and transforms the cancer into a chronic disease, which greatly extends the survival time of the patient.

          The clinical trial of this therapeutic vaccine has been conducted in Cuba with local drug registration. Meanwhile, many countries and regions in Europe and Asia have launched the registration trials of the vaccine and have gained positive preliminary results. At present, the vaccine is being converted into product for China.

          The Cancer Hospital of CAMS is the partner of the Phase I clinical trial of the project. Vice-president professor, Shi Yuankai, confirmed that the new vaccine will first enter the Phase I clinical trial in the hospital starting in March. Dr. Lage predicted that after two years of clinical trials, the new anticancer vaccine will be put into the market.

          As the largest project of the China-Cuba biological cooperation, Biotech has acquired spectacular results in the field of biopharmaceutical anticancer. During its development in the past decade, Biotech has made remarkable achievements in tumor research and treatment and created the first domestic antibody humanization technology platform at a world leading level.

          The company has also designed and constructed China's first full-automatic and large-scale mammalian cell culture production line, and researched and developed Nimotuzomab - the first humanized monoclonal antibody of gene recombination for malignant tumor treatment.

          Edited by Chen Zhilin and Rakhee M

           

          Zhang Hui

          Zhang Hui, Board Chairman and Chief Executive Officer of Beijing Innofidei.

           

          Yu Zhenhua

          Yu Zhenhua, Board Chairman of Beijing Prudent Energy Inc.

           

          Deng Zhonghan

          Deng Zhonghan, Board Chairman of Vimicro.

           
           

          Zhongguancun Science Park

          主站蜘蛛池模板: 国产SM重味一区二区三区| 亚洲AV永久无码嘿嘿嘿嘿| 老司机免费的精品视频| 东京热人妻丝袜无码AV一二三区观| 国产精品中文字幕自拍| 在线观看成人永久免费网站| 97精品伊人久久久大香线蕉| 亚洲高潮喷水无码AV电影| 99国精品午夜福利视频不卡99| 日本特黄特色aaa大片免费| 任我爽精品视频在线播放| 免费网站看V片在线毛| 亚洲av成人在线网站| 成在人线AV无码免观看麻豆| 亚洲欧美日韩在线不卡| 国产精品一区二区久久岳| 亚洲最大成人av免费看| 亚洲熟妇av综合一区二区| 久久热这里只有精品66| 日韩精品专区在线影观看| 玩弄丰满少妇人妻视频| 国产特级毛片aaaaaa高清| 乱人伦中文字幕成人网站在线| 日韩av中文字幕有码| 痉挛高潮喷水av无码免费| 99re视频精品全部免费| 免费人妻无码不卡中文18禁| 久久99日韩国产精品久久99| 二区中文字幕在线观看| 国产情侣激情在线对白| 精品无码一区二区三区爱欲| 正在播放肥臀熟妇在线视频| 在线亚洲妇色中文色综合| 亚洲欧美自偷自拍视频图片| 亚洲综合无码明星蕉在线视频| 国内少妇人妻偷人精品视频| 国产av一区二区三区区别 | 国产精品久久久久aaaa| 欧美白妞大战非洲大炮| 亚洲中文无码av永久app| julia中文字幕久久亚洲|